These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34915285)

  • 1. Discovery of N-(1,3,4-thiadiazol-2-yl)benzamide derivatives containing a 6,7-methoxyquinoline structure as novel EGFR/HER-2 dual-target inhibitors against cancer growth and angiogenesis.
    Li XY; Wang DP; Li S; Xue WH; Qian XH; Liu KL; Li YH; Lin QQ; Dong G; Meng FH; Jian LY
    Bioorg Chem; 2022 Feb; 119():105469. PubMed ID: 34915285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of novel quinazoline-derived EGFR/HER-2 dual-target inhibitors bearing a heterocyclic-containing tail as potential anti-tumor agents.
    Hao S; Wang JH; Hou L; Liang JW; Yan JH; Niu YF; Li XY; Sun Q; Meng FH
    Bioorg Chem; 2024 Oct; 151():107686. PubMed ID: 39111120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
    Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
    Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Benzamide-Chalcone Derivatives as EGFR/CDK2 Inhibitor: Synthesis, In-Vitro Inhibition, and Molecular Modeling Studies.
    Joshi A; Bhojwani H; Wagal O; Begwani K; Joshi U; Sathaye S; Kanchan D
    Anticancer Agents Med Chem; 2022; 22(2):328-343. PubMed ID: 33858315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR.
    Wassel MMS; Ammar YA; Elhag Ali GAM; Belal A; Mehany ABM; Ragab A
    Bioorg Chem; 2021 May; 110():104794. PubMed ID: 33735711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Zou M; Li J; Jin B; Wang M; Chen H; Zhang Z; Zhang C; Zhao Z; Zheng L
    Bioorg Chem; 2021 Sep; 114():105200. PubMed ID: 34375195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
    Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB
    Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models.
    Das D; Xie L; Wang J; Shi J; Hong J
    Bioorg Chem; 2020 Jun; 99():103790. PubMed ID: 32279037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFR
    Zhao L; Fan T; Shi Z; Ding C; Zhang C; Yuan Z; Sun Q; Tan C; Chu B; Jiang Y
    Eur J Med Chem; 2021 Mar; 213():113173. PubMed ID: 33493830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.
    Wei H; Duan Y; Gou W; Cui J; Ning H; Li D; Qin Y; Liu Q; Li Y
    Eur J Med Chem; 2019 Nov; 181():111552. PubMed ID: 31387063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a prominent dual-target DDR1/EGFR inhibitor aimed DDR1/EGFR-positive NSCLC.
    Wang X; Lu Y; Chen S; Zhu Z; Fu Y; Zhang J; He J; Huang L; Luo L; Guo W; Xu Z; Xie Z; Xu X; Zhang Y; Ye F; Ma S
    Bioorg Chem; 2024 Aug; 149():107500. PubMed ID: 38823310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
    Diaz R; Nguewa PA; Parrondo R; Perez-Stable C; Manrique I; Redrado M; Catena R; Collantes M; Peñuelas I; Díaz-González JA; Calvo A
    BMC Cancer; 2010 May; 10():188. PubMed ID: 20459769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
    Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
    Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
    Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
    Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
    Hou W; Ren Y; Zhang Z; Sun H; Ma Y; Yan B
    Bioorg Med Chem; 2018 May; 26(8):1740-1750. PubMed ID: 29523467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis,
    Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
    Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
    Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
    Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel dihydropyrimidines as promising EGFR & HER2 inhibitors: Insights from experimental and computational studies.
    Faizan S; Wali AF; Talath S; Rehman MU; Sivamani Y; Nilugal KC; Shivangere NB; Attia SM; Nadeem A; Elayaperumal S; Kumar BRP
    Eur J Med Chem; 2024 Sep; 275():116607. PubMed ID: 38908102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.
    Li DD; Qin YJ; Sun J; Li JR; Fang F; Du QR; Qian Y; Gong HB; Zhu HL
    PLoS One; 2013; 8(8):e69427. PubMed ID: 23936329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors.
    Xiao Z; Chu C; Zhou L; Zhou Z; Zhang Q; Yang F; Yang Z; Zheng P; Xu S; Zhu W
    Bioorg Med Chem; 2020 Oct; 28(19):115669. PubMed ID: 32912435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.